DBV Technologies SA Sustainability Reports
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focused on developing therapies for food allergies and other immunologic conditions. Its proprietary technology platform, Viaskin, delivers allergens via an epicutaneous patch to desensitize patients.
Sector: Manufacturing
Country: France
Exchange: Euronext Paris
LEI: 969500PVBQFWQKVDMD80
FIGI: BBG002GJZV72
11 reports from 2016 to 2025
